Herbalife Exceeds Q4 & FY25 Guidance, Cristiano Ronaldo Invests $7.5M in Pro2col Technology
summarizeSummary
Herbalife reported strong Q4 and full-year 2025 financial results, surpassing guidance, and announced a strategic $7.5 million investment by Cristiano Ronaldo in its Pro2col technology.
check_boxKey Events
-
Exceeded Q4 and Full-Year 2025 Financial Guidance
Herbalife reported fourth-quarter 2025 net sales of $1.3 billion, up 6.3% year-over-year, and full-year 2025 net sales of $5.0 billion, up 0.9%, both exceeding guidance. Adjusted EBITDA also surpassed guidance for both periods, reaching $156.1 million for Q4 and $657.6 million for the full year.
-
Cristiano Ronaldo Invests in Pro2col Technology
Global sports icon Cristiano Ronaldo invested $7.5 million for a 10% equity stake in HBL Pro2col Software, LLC, Herbalife's personalized health and wellness operating system. This investment includes a commitment to provide services and sponsorship rights, underscoring a strategic partnership.
-
Improved Financial Health and Liquidity
The company's total leverage ratio improved to 2.8x at December 31, 2025, down from 3.2x in 2024. Net cash provided by operating activities for the full year was $333.3 million, and the revolving credit facility was undrawn at year-end.
-
Provided Positive 2026 Outlook
Herbalife issued guidance for the first quarter and full-year 2026, projecting net sales growth of 3.0% to 7.0% year-over-year for Q1 and 1.0% to 6.0% for the full year, alongside adjusted EBITDA guidance of $670 million to $710 million for 2026.
auto_awesomeAnalysis
Herbalife's strong financial performance, exceeding both fourth-quarter and full-year 2025 guidance for net sales and adjusted EBITDA, signals operational momentum. The significant strategic investment by global sports icon Cristiano Ronaldo in Herbalife's Pro2col technology is a major positive, providing not only capital but also a powerful endorsement and sponsorship rights. This partnership could substantially boost the visibility and adoption of Herbalife's personalized health and wellness platform. Furthermore, the company's improved leverage ratio and undrawn credit facility demonstrate enhanced financial stability, positioning it well for future growth initiatives outlined in its 2026 guidance.
At the time of this filing, HLF was trading at $18.78 on NYSE in the Trade & Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $5.57 to $17.93. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.